Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:23 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 251 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Adult Males Clear all

Conditions: Vaccine, Crimean-Congo Hemorrhagic Fever
Interventions: 10 ug HDT 321, 25ug HDT-321, 50ug HDT-321; Biological
Lead sponsor: HDT Bio; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Subjects
Interventions: E2609, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 30 Years to 60 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Participants
Interventions: Oral [14C]PF-06865571, Oral PF-06865571, IV [14C]PF-06865571; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: Ritlecitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Healthy Adult Male
Interventions: [14C]-VVZ-149; Drug
Lead sponsor: Vivozon, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Overactive Bladder
Interventions: Solabegron; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Healthy Subject
Interventions: HMS5552; Drug
Lead sponsor: Hua Medicine Limited; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Erectile Dysfunction
Interventions: ASP-001, Viagra, ASP-001; Drug · Device
Lead sponsor: Aspargo Labs, Inc; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Healthy Male Volunteer
Interventions: JNJ-38518168 (30 mg), JNJ-38518168 (10 mg), JNJ-38518168 (3 mg), Placebo, Midazolam and JNJ-38518168; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy
Interventions: Endoflip measurement of gastric and pyloric function; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Adult Male and Female Volunteers
Interventions: Low-frequency whole-body vibration mat; Device
Lead sponsor: Florida International University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Alzheimer's Disease
Interventions: CTS21166 (ZPQ-21166); Drug
Lead sponsor: CoMentis; Industry
Eligibility: 22 Years and older · Male only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: Levetiracetam; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Renal Impairment
Interventions: Drug: PF-07923568; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Orlando, Florida • Tampa, Florida • Saint Paul, Minnesota + 1 more

Conditions: Healthy
Interventions: PF-04991532; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Healthy
Interventions: Finasteride; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions: SAR443820; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Healthy Volunteers
Interventions: [14C]-plazomicin; Drug
Lead sponsor: Achaogen, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: [14C]-HU6; Drug
Lead sponsor: Rivus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy
Interventions: Ecopipam immediate release form, 90 mg controlled release form, 180 mg controlled release form; Drug
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Subjects
Interventions: Placebo, mirabegron, moxifloxacin; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 352 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Renal Impairment, Healthy Adults
Interventions: Prifetrastat; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Miami Lakes, Florida • Tampa, Florida • Saint Paul, Minnesota

Conditions: Healthy
Interventions: MTP-131 (Bendavia™); Drug
Lead sponsor: Mighty Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: PAH
Interventions: TransCon PEG treprostinil; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 50 Years · Male only
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2609 in Healthy Adult Male Japanese and White Subjects

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food

Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects

A Two-Part Study to Determine: Best Medication Formulation and Food Effect

Human Mass Balance Study of HMS5552 in Healthy Subjects

Study to Compare the Effects of Viagra® Vs Hezkue® in Healthy Fasted Male Participants.

A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam

A Study to Evaluate Endoflip Normal Ranges Data in Healthy Volunteers

Evaluating a Mat-Based Biometric Vibration System for Sleep and Daily Recovery

Safety Study of CTS21166 to Treat Alzheimer Disease

Bioequivalence Study of Levetiracetam Tablets, 750 mg of Dr. Reddy's Under Fed Conditions

A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function

Single Dose Study To Study The Absorption, Metabolism And Excretion Of PF-04991532

Bioequivalence Study of Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions

A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)

A Study to Assess the Metabolism, Excretion, and Mass Balance of Radio-Labeled Plazomicin

A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6

Safety and Tolerability Comparison of Immediate and Controlled Release Formulations of Ecopipam

A Study to Evaluate the Effect of Oral Mirabegron on the Heart in Healthy Males and Females

A Study to Learn About the Study Medicine Called Prifetrastat in People With Renal Impairment

Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of Intravenous (IV) Infusion of MTP-131 (Bendavia™) in Healthy Adults

Dose Escalation, MTD, Safety and PK Study of a Single Dose SC Injection of TransCon PEG Treprostinil in Healthy Male Volunteers